Associate Director, Research – European Pharmaceuticals and Biotechnology Regulation

Job Description

POLITICO is seeking an Associate Director, Research to help lead part of its regulatory intelligence and information services product, AgencyIQ. Since its founding in early 2020, AgencyIQ has quickly become the premier source of regulatory intelligence and analysis for professionals working in the life sciences, foods and chemicals industries.

Our written research and analysis is relied upon by many top companies, trade groups, law firms and advocacy groups to help them understand breaking news, identify emerging trends, predict future action and prepare for seismic shifts in regulatory policy.

As a subject matter expert in the regulation of pharmaceuticals, biopharmaceuticals and biotech in Europe – by the European Medicines Agency and other European regulatory authorities – the Associate Director will be responsible for analyzing the relevance of regulatory changes and developments, articulating the type and degree of impact on industry, and providing context to an audience of knowledgeable regulatory professionals.

We’re looking for a regulatory expert who is as knowledgeable about regulatory topics as they are capable of explaining complex subjects to others quickly and effectively.

Reporting to the Senior Director for Life Sciences Research, the Associate Director will join a team of experienced researchers responsible for producing a mix of daily written content, in-depth written research, weekly insights, directed deliverables and presentations.

This role can be based at POLITICO’s headquarters in Arlington, Virginia or at POLITICO’s European offices in London or Brussels.

What You’ll Do

• Produce daily (3-4 per week) topical intelligence articles and other content for our subscribers based on emerging regulatory and legislative developments and trends
• Serve as a subject matter specialist on matters of related to how European life sciences regulatory agencies regulate pharmaceuticals, biopharmaceuticals, biotechnology products, biosimilars, generic drugs, and nonprescription products
• Lead or participate in the development and delivery of in-depth analysis, deep-dive research, webinars and email newsletters
• Participate in subscriber- and prospect-facing events and regular briefings

What You’ll Need

• At least 7 years’ experience analyzing European life sciences regulatory policies at a consulting company, think tank, trade association, government agency, life sciences company, or media outlet
• An affinity for writing – efficiently and effectively, and for a business or policy audience – paired with a knowledge of (and passion for) regulation and regulatory policy
• Advanced-level (and preferably expert-level) knowledge of European regulatory processes related to drug and biotechnology products; capable of delivering expert insights to our knowledgeable subscribers
• Experience and comfort working in fast-paced, research-driven environments in which daily delivery of written regulatory analyses of new information is the norm
• Experience with qualitative and quantitative analysis and trend tracking

While Not Required, You Will Stand Out If You

• Have an advanced degree or certification related to the life sciences (i.e., a PhD, relevant master’s degree, or J.D.)
• Have prior experience working in media, including as a journalist or writing a product widely read by others (i.e., a business intelligence product or internal newsletter)
• Have experience in quantitative analysis using EMA data sets
• Experience presenting on regulatory topics to a variety of different audience types (small groups, large groups) in different environments (virtual and in-person)

We value our people. Click here for more on what we offer and what it’s like to work for POLITICO.

Let’s keep in touch. You can view our list of open positions here.

About Us.

POLITICO illuminates the forces shaping global power. Since 2007, we have delivered intelligence that anticipates tomorrow's headlines, not reports on yesterday's news. As politics has increasingly become the defining force of our era, our work has never been more vital.

Cabinet secretaries and Ministers start their mornings with our analysis. CEOs shape strategy around our reporting. Advocacy leaders rely on our insights to move policy. We deliver the straightforward facts and clear-eyed analysis they need to navigate the most complex political landscape of our lifetimes.

Our 1,100+ publishing professionals across the world's key democratic capitals—Washington, Brussels, London, Paris, Berlin, Sacramento, and New York—form the world's premier politics and policy newsroom. We tell the story of how power really works by explaining who wields it and how they plan to exercise it, connecting dots others miss and delivering scoops from sources others don't even know exist.

Innovation has always been a core tenet of our story. At launch, we bet that depth would trump scale, that talent would trump traffic, and that politics would become central to modern life. In 2011, we made another bet and launched POLITICO Pro to help decision-makers understand the business of government, transforming both how they shape government action and the business of journalism itself.

These bets have made POLITICO the most successful digital news startup of its generation and the indispensable resource for leaders who shape the future. Today, we are a rarity in media: a growing, profitable, and sustainable news organization.

POLITICO is a subsidiary of Axel Springer SE, a family-owned transatlantic media company headquartered in Berlin and New York. Axel Springer is dedicated to shaping the future of journalism in the free world, believing that a free and informed society is essential to democracy. The company’s guiding principles - first articulated as The Essentials by founder Axel Springer in the aftermath of World War II - remain a cornerstone of the company’s foundation today. Learn more about Axel Springer.

Posting Date

2026-04-07

Title

Associate Director, Research – European Pharmaceuticals and Biotechnology Regulation